Nevirapine

Clinical Immunotherapeutics

Volumn 6, Issue 4, 1996, Pages 307-317

  Patel, Sanjay S ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CASTANOSPERMINE 6 BUTYRATE; DIDANOSINE; EMIVIRINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG RESISTANCE; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SOMNOLENCE; VIRUS REPLICATION;

EID: 0029780947     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259093     Document Type: Review

References (56)

1. Richman D. Rosenthal AS. Skoog M. et al. BI-RG-587 is active against J.idovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.Antimicrob Agents Chemolher 1991 Feh: 35 (2): 305-8
2. Merlu VJ. Margrave KD. Labadia M. et al. Inhibition of HI VI replication by a nonnudeoside reverse transcriptase inhibitor. Science 1990 Dec: 250 (4986): 1411-3
3. Skoog MT. Hargrave KD. Miglietta JJ. el al. Inhibition of HI V-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodia/epinone BI-RG-587 (Nevirapine). Med Res Rev 1992 Jan: 12(1): 27-40
4. Kohlstaedt LA, Wang J. Hriednian JM. et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complcxed with an inhibitor. Science 1992 Jun: 256: 1783-90
5. Furftne ES. Reardon JE. Human immunodeficiency virus reverse transcriptase ribonuelease H: specificity of tRNAl>siprimer excision. Biochemistry 1991 Jul; 30(29): 7041 6
6. Palladino DEH. Hopkins JL. Ingraham RH. el al. Highperformance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus type I. J Chromatogr A 1994 Jul: 676: 99-112
7. Condra JH. Emini EA. Gotlib L. et al. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnudeoside inhibitors. Antimicrob Agents Chemother 1992 Jul; 36 (7): 1441 6
8. Wu JC. Warren TC, Adams J. et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 1991 Feb: 30(8): 2022-6
9. Spence RA. Kati WM. Anderson KS.etal. Mechanism of inhibition of HI V-1 reverse transcriptase by nonnudeoside inhib itors. Science 1995 Feb: 267: 988-93
10. Palaniappan C. Fay PJ. Bambara RA. Nevirapine alters the cleavage specificity of ribonuelease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chetn 1995 Mar: 270(91:4861-9
11. Tramontano E, Cheng Y-C. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 1992 Mar: 43 (6): 1371-6
12. Koup RA. Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodia/epinone BI-RG-587. J Infect Dis I99I May; 163: 966-70
13. Rusconi S. Merrill DP, Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 1994 Dec: 170: 1361-6
14. Merrill DP. Moonis M. Chou T-C. et al. Lamivudine or sta\ udine in two- and three-drug combinations against human immunodeficiency virus type I replication in vitro. J Infect Dis 1996 Feb; 173:'355-64
15. Taylor DL. Brennan TM. Bridges CG. et al. Synergistic inhibi tion of human immunodeficiency virus type I in vitro by 6O-butanoylcastanospermine (MDL28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antiviral Chem Chemother 1995 May: 6 (3): 143-52
16. Connell EV. Hsu M-C. Richman DD. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HI V protease inhibitor. Antimicrob Agents Chemother 1994 Feb; 38 (2): 348-52
17. Brennan TM. Taylor DL. Bridges CG. et al. The inhibition of human immunodeficiency virus type I in vitro by a non-nucleoside reverse transeriptase inhibitor MKC-442. alone and in combination with other anti-HIV compounds. Antiviral Res 1995 Mar: 26: 173-87
18. Maz/ulli T. Rusconi S, Merrill DP. et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994 Apr; 38 (4): 656-61
19. Oh M-D, Merrill D, Hirsch M, et al. Simultaneous vs sequential combination regimens for the treatment of HIV-1 infection in vitro [abstract no. B.3135). Proceedings of the 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver, Canada, 79u
20. Koup RA, Brewsler F, Grob P, et al. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine. Interferon or CD4 immunoadhesin. AIDS 1993 Sep; 7 (9): 1181-4
21. Richman D, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sei USA 1991 Dec; 88: 11241-5
22. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1 -specific pyridinone reverse transcriptase inhibitors. J Virol 1991 Sep; 65 (9): 4887-92
23. Sardana VV, Emini EA, Gotlib L, et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem 1992 Sep; 267 (25): 17526-30
24. De Clercq E. HIV resistance lo reverse transcriptase inhibitors. Biochem Pharmacol 1994 Jan; 47 (2): 155-69
25. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1995; 3 (1): 8-13
26. Shih C-K, Rose JM, Hansen GL, et al. Chimeric human immunodeficiency virus type 1 /type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sei USA 1991 Nov; 88: 9878-82
27. Byrnes VW, Emini EA, Schleif WA, et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1994 Jun; 38 (6): 1404-7
28. Emini EA, Graham DJ, Gotlib L, et al. HIV and multidrug resistance [letter]. Nature 1993 Aug; 364: 679
29. Larder B A, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro [letter]. Nature 1993 Sep; 365: 451-3
30. Balzarini J, Karlsson A, Pérez-Pérez M-J, et al. Treatment of human immunodeficiency virus type-1 (HIV-1 (-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with singledrug therapy. J Virol 1993 Sep; 67 (9): 5353-9
31. Balzarini J, Karlsson A, Pérez-Pérez M-J, et al. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drugresistant virus. Virology 1993 Oct; 196: 576-85
32. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993 Feb; 37 (2): 178-82
33. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995 Mar; 171:537-45
34. Mirochnick M, Sullivan J, Cort S, et al. Safety and pharmacokinetics (PK) or nevirapine (N VP) in HIV-1 infected pregnant women and their newborns [abstract no. 444]. Pediatr Res 1996 Apr; 39 (2): 76A
35. Riska P, Erickson D, Joseph D, et al. Nevirapine, a nonnucleoside reverse transcriptase inhibitor: metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee [abstract no. B.2326]. Proceedings of the 1 Hh International Conference on AIDS; 1996 Jul 7-12; Vancouver, Canada, 321
36. De Jong M. Antiviral response to nevirapine monotherapy in nucleoside naive persons [abstract no. PB0847]. Proceedings of the 10th International Conference on AIDS; 1994 Aug 712; Yokohama, Japan, 208.
37. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndrom Hum Retrovirol 1995 Feb; 8 (2): 141-51
38. de Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1 -infected persons does not prolong nevirapine activity. J Infect Dis 1994 Jun; 169: 1346-50
39. Loewenthal M, Hall D, de Jong MD, et al. Treatment with nevirapine and zidovudine in antiretroviral naive HIV-1 infected patients [abstract no. PO-B26-2101]. Proceedings of the 9th International Conference on AIDS; 1993 Jun 6-11; Berlin, Germany, 485
40. Carr A, Vella S, De Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996; 10: 635-41
41. Paar D, Pollard R, Hall D, et al. Nevirapine (NVP) in combination with zidovudine (ZDV) vs ZDV in nucleoside experienced patients [abstract no. 383]. Clin Infect Dis 1995 Sep; 21 (3): 783
42. Saag M, Johnson V, Wei X, et al. Clinical, pharmacokinetic, and virologie results in adults treated with nevirapine (Nev) in combination with AZT/ddC, AZT/ddl, or ddl alone: final report of the BI1009 study [abstract no. M16[. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando, Florida, 218
43. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996 Jun; 124(12): 1019-30
44. Study BI 1046: interim (28-week) results. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT. Data on file
45. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994 Mar; 68 (3): 1660-6
46. Havlir D, McLaughlin MM, Richman DD. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995 Nov; 172: 1379-83
47. Mueiler BU, Sei S, Luzuriaga K, et al. The impact of combination therapy (zidovudine + didanosine + nevirapine) on HIV-1 virus burden in peripheral blood and lymph node tissue in children [abstract], J Invest Med 1995 Apr; 43 (2) Suppl. 2: 249A
48. Wei X, Johnson V, Taylor M, et al. Rapid HIV-1 turnover in patients receiving combination nevirapine (Nev) therapy [abstract no. 164]. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando, Florida, 61
49. Luzuriaga K, Sullivan JL. Pharmacokinetics, safety and activity of nevirapine in HIV-1 infected children [lecture). Non-nucleoside reverse transcriptase inhibitors: a new class of antiretrovirals; 1996 Jul 9; Vancouver, Canada
50. Myers MW, Montaner JG, The Incas Study Group. A randomized, double-blinded comparative trial of the effects of zidovudine, didanosine and nevirapine combinations in antiviral naive, AIDS-free, HIV-infected patients with CD4 counts 200-600/mm' (abstract no. B.294]. Proceedings of the llth International Conference on AIDS: 1996 Jul 7-12; Vancouver. Canada, 22
51. Tomino C, Fragola V, Bucciardini R, et al. Tolerability of AZT+DDI and AZT+DDI+nevirapine among antiretroviralnaive patients with advanced HIV infection (AIDS or CD4+ <2(X)/mm1): preliminary results [abstract no. B.2I19). Proceedings of the 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver, Canada, 285
52. Burchett SK, Luzuriaga K, Culnane M, et al. Early toxicity experience in combination therapy of advanced pédiatrie HIV disease [abstract no. 1264], Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20: San Francisco, California, 253
53. Cheeseman SH, Murphy RL, Saag MS, et al. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in [abstract no. PO-B26-2I09|. Proceedings of the 9th International Conference on AIDS; 1993 Jun 6-11; Berlin, Germany. 487
54. Kohlbrenner V, Dransfield K, Cotton D, et al. Cutaneous eruptions associated with nevirapine (NVP) therapy in HIV-1 infected individuals [abstract no. B.1202|. Proceedings of the 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver. Canada, 89
55. Grob PM, Wu JC, Cohen KA. et al. Nonnucleoside inhibitors of HIV-1 reverse transcripta.se: nevirapine as a prototype drug. AIDS Res Hum Retroviruses 1992 Feb; 8 (2): 145-52
56. Weinberg RS. Chusid ED. Galperin Y. et al. Nevirapine (Nev) is less toxic to progenitor cells (BFU-E) than AZT or ddl [abstract no. PB0813]. Proceedings of the 10th International Conference on AIDS; 1994 Aug 7-12: Yokohama, Japan. 200